Rigel就其免疫性血小板减少症治疗的专利诉讼达成和解

2025-03-27 21:59

Rigel Pharmaceuticals (RIGL) announced a settlement agreement with Annora Pharma Private, Hetero Labs, and Hetero USA, resolving an ongoing patent dispute related to TAVALISSE, the company's treatment for chronic immune thrombocytopenia.
As part of the agreement, Annora has been granted a license to sell its generic version of TAVALISSE starting in Q2 2032, or earlier under specific conditions.
The litigation stemmed from Annora’s submission of an Abbreviated New Drug Application to the U.S. FDA, seeking approval to market a generic version of TAVALISSE in the United States.
With this settlement, the company said that all ongoing legal proceedings between Rigel and Annora regarding TAVALISSE patents in New Jersey have been dismissed.

More on Rigel Pharmaceuticals